GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (FRA:LSRM) » Definitions » Cyclically Adjusted PB Ratio

CEL-SCI (FRA:LSRM) Cyclically Adjusted PB Ratio : (As of May. 20, 2024)


View and export this data going back to 2000. Start your Free Trial

What is CEL-SCI Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CEL-SCI Cyclically Adjusted PB Ratio Historical Data

The historical data trend for CEL-SCI's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Cyclically Adjusted PB Ratio Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 3.01 4.21 1.59 1.22

CEL-SCI Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 2.03 1.22 3.42 -

Competitive Comparison of CEL-SCI's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, CEL-SCI's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEL-SCI's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Cyclically Adjusted PB Ratio falls into.



CEL-SCI Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CEL-SCI's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, CEL-SCI's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.253/131.7762*131.7762
=0.253

Current CPI (Mar. 2024) = 131.7762.

CEL-SCI Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.189 100.560 5.489
201409 2.474 100.428 3.246
201412 2.624 99.070 3.490
201503 0.087 99.621 0.115
201506 0.781 100.684 1.022
201509 -0.944 100.392 -1.239
201512 0.623 99.792 0.823
201603 -0.489 100.470 -0.641
201606 -0.579 101.688 -0.750
201609 -0.097 101.861 -0.125
201612 0.550 101.863 0.712
201703 -0.332 102.862 -0.425
201706 0.009 103.349 0.011
201709 -0.235 104.136 -0.297
201712 -0.308 104.011 -0.390
201803 -0.149 105.290 -0.186
201806 -0.055 106.317 -0.068
201809 0.000 106.507 0.000
201812 0.085 105.998 0.106
201903 0.028 107.251 0.034
201906 0.030 108.070 0.037
201909 0.132 108.329 0.161
201912 0.174 108.420 0.211
202003 0.296 108.902 0.358
202006 0.438 108.767 0.531
202009 0.432 109.815 0.518
202012 0.596 109.897 0.715
202103 0.604 111.754 0.712
202106 1.155 114.631 1.328
202109 1.112 115.734 1.266
202112 1.051 117.630 1.177
202203 0.946 121.301 1.028
202206 0.845 125.017 0.891
202209 0.748 125.227 0.787
202212 0.574 125.222 0.604
202303 0.430 127.348 0.445
202306 0.305 128.729 0.312
202309 0.261 129.860 0.265
202312 0.232 129.419 0.236
202403 0.253 131.776 0.253

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CEL-SCI  (FRA:LSRM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CEL-SCI Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CEL-SCI (FRA:LSRM) Business Description

Industry
Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

CEL-SCI (FRA:LSRM) Headlines

No Headlines